Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after receiving the initial results from its LPS human challenge clinical study for its molecule POLB 001, that he hopes will eventually help in treating severe influenza.
Skillington says that there were "no severe adverse events" reported among the 36 healthy volunteers.